Domain Associates-backed Aldexa Therapeutics Raises $4.8 Million
Aldexa Therapeutics Inc. has raised $4.8 million, or over 50% of an $8.8 million offering of shares and options, according to an SEC filing. Two investors bought the securities.
Burlington, Mass.-based Aldexa, previously known as Neuron Systems Inc., last raised $8.96 million in 2008, its only other round on record.It is backed by Princeton, N.J.-based Domain Associates and Johnson & Johnson Development, of New Brunswick, N.J.
Aldexais developing drugs to treata dry form of age-related macular degeneration, an eye disease that could lead to blindness. Even though the condition affects millions of individuals worldwide, there are no approved drugs to treat dry AMD.
Led by development experts and ophthalmology industry veterans, Aldexa’s board includes Jerry Cagle (formerly of Alcon Laboratories), Gary Phillips (formerly of Bausch + Lomb) and John Dowling (Harvard).
Founded in 1985, Domain Associates is a venture capital firm with exclusive focus on the life sciences. It has $2.4 billion of capital under management.